Document:

FORBEARANCE
AGREEMENT

This
FORBEARANCE AGREEMENT (this "Agreement"), effective as of the last date of signature below (hereinafter the "Effective
Date"), is entered into by and among Antigen Express, Inc. ("Antigen Express") and Generex Biotechnology Corporation
("Generex," and together with Antigen Express the "Companies") and The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Inc. (the "Foundation"). The Companies and Foundation sometimes are referred to collectively
as the "Parties" or individually as a "Party." 

WHEREAS,
the Foundation and Antigen Express entered into that certain Clinical Study Agreement effective February I, 2007 as amended
("Clinical Study Agreement" or "CSA") to establish terms and conditions for the Institution's (as defined
in the CSA) performance of the Study (as defined in the CSA);

WHEREAS,
the Companies acknowledge that as of September 1, 2013 Antigen Express is One Million Three Hundred Fifteen Thousand Eight
Hundred and Seventeen Dollars and Thirty Eight Cents ($1,315,817.38) in arrears in its payment and interest obligations to the
Foundation under the Clinical Study Agreement and this constitutes the initial Forbearance Amount (as defined below) under this
Agreement;

WHEREAS,
based on Antigen Express' payment delinquency under the Clinical Study Agreement, the Foundation is entitled to terminate
the Clinical Study Agreement;

WHEREAS,
the Companies have requested the Foundation to forbear from exercising its right to terminate the Clinical Study Agreement
due to Antigen Express' payment delinquency during a Forbearance Period (as defined below); and

WHEREAS,
Foundation has expressed its willingness to defer Antigen Express' overdue payments, future payments, and interest as required
under the Clinical Study Agreement during the Forbearance Period (as defined below), and in consideration for Foundation deferring
Antigen Express' overdue payments, future payments, and interest, the Companies have agreed, among other things, to pay Foundation
certain royalties and accelerated payments as further described herein.

NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby expressly acknowledged, the Parties agree as follows:

1.
DEFINITIONS:

 

(a) "Forbearance Amount" means all past due and outstanding payments, future payments (as they become
due), and interest required under the CSA.

 

(b)
"Forbearance Payments" means the royalty payments required to be made by the Companies to the Foundation under this
Agreement.

 

(c) "Forbearance Period" means the period commencing with the Effective Date and ending on the earliest to
occur of (i) the Companies buying out its

(d)
"Net Sales" means all amounts (including the fair market value of any non cash consideration) billed, invoiced, or received
(whichever first occurs) for sales, leases, or other transfers of the Vaccine, less the sum of the following:

 

i.
customary trade, quantity, or cash discounts actually allowed and taken;

 

ii.
amounts repaid or credited by reason of rejection or return;

 

iii.
to the extent separately stated on purchase orders, invoices, or other documents of sale, sales taxes, tariff duties, and use
taxes directly imposed on sale, transportation, delivery, or use and paid by or on behalf of Antigen Express;

  

iv.
reasonable charges for delivery or transportation provided by non affiliated third parties, if separately stated and prepaid or
actually allowed; and

 

v.
rebates paid to a group purchasing organization.

 

No deductions shall
be made for commissions paid to individuals, whether they are with independent sales agencies or regularly employed by and on
the payroll of the Companies.

 

(e)
"Vaccine" means a breast cancer vaccine using AE37 alone or in combination. Clinical development and
commercialization of AE37 and/or Ii-Key initiatives for uses other than as a breast cancer vaccine are outside the scope of
this Agreement.

 (f) Capitalized terms used herein and not otherwise defined shall have the same meaning herein as in the CSA.

2.
FORBEARANCE

 

During
the Forbearance Period, unless otherwise expressly provided in this Agreement, the Foundation will not take any action to terminate
the CSA based solely on the Companies' failure to pay the Forbearance Amount. At the end of the Forbearance Period, the Foundation
shall be entitled to exercise any of its rights under this Agreement, the CSA, or applicable law based on the Companies' failure
to pay the Forbearance Amount.

3.
ACCELERATION PAYMENT

 

Under
the CSA, Antigen Express is required to pay the Foundation a final payment of $200,000 upon completion of all subjects and
receipt and acceptance by Antigen Express of all required documents. The Companies agree to accelerate this $200,000 payment
("Acceleration Payment") such that the Acceleration Payment shall be payable out of, and a first charge on, any
amounts received by the Companies from a third party in respect of or relating to the continued clinical
development/commercialization of the breast cancer indication for the Vaccine.

 4. FORBEARANCE
PAYMENTS

 (a) The Companies shall pay to the Foundation royalties in the following amounts based on the Companies' actual receipt of third party royalty payments in respect of Net Sales of the Vaccine as follows:

 i. to the extent that such third party royalty payments to the Companies are less than ten percent (10%) of third party Net Sales of the Vaccine (the "Level One Royalty"), the Forbearance Payments to the Foundation will be an amount equal to fifty percent (50%) of the Level One Royalty;

ii.
to the extent that such third party royalty payments to the Companies are equal to or greater than ten percent (10%) of third
party Net Sales of the Vaccine, the Forbearance Payments to the Foundation will be an amount equal to five percent (5%) of third
party Net Sales of the Vaccine;d

 

iii.
If, and to the extent that, the Companies directly engage in the marketing, distribution, and sale of the Vaccine, the Forbearance
Payments will be an amount equal to five percent (5%) of Net Sales of the Vaccine; and

 

iv.
if third party royalty payments in respect of the commercialization of the Vaccine that are calculated other than with reference
to Net Sales of the Vaccine, the Companies and the Foundation will revise the calculation methodologies in paragraphs (i) and
(ii) above to approximate the Forbearance Payments that would have otherwise been payable.

 

(b)
All Forbearance Payments shall be made within thirty (30) days of the date of actual receipt by the Companies. Forbearance payments
shall be paid by check or by wire transfer in United States dollars in Bethesda, Maryland, or at such other place and manner as
the Foundation may designate in writing.

 

(c)
All Forbearance Payments due hereunder shall be paid in full, without deduction for any taxes or other fees imposed by any government
or any transfer, collection, or similar charges; any such tax, fee, or charge shall be paid by the Companies.

 

(d)
The Companies shall keep, and shall require its licensees to keep, accurate records (together with supporting documentation) of
Net Sales of the Vaccine appropriate to determine the amount of Forbearance Payments due the Foundation hereunder. Such records
shall be retained for at least three (3) years. They shall be available during normal business hours for examination by an accountant
selected by the Foundation, for the sole purpose of verifying payments hereunder. In conducting examinations pursuant to this
section, the Foundation's accountant shall have access to all records that the Foundation reasonably believes to be relevant to
the calculation of Forbearance Payments hereunder. In cases of inaccurate payments, the Companies shall promptlyp ay the Foundation
any additional sum that would have been payable to the Foundation plus interest on said sum at the rate of one and one half per
cent (I 1/2%) per month. Such examination by the Foundation's accountant shall be at the Foundation's expense, except that if
such examination shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period,
then the Companies shall pay the Foundation the cost of such examination (as well as any additional sum that would have been payable
to the Foundation plus interest on said sum at the rate of one and one half per cent (I 1/2%) per month).

 

5.
BUY-OUT OF FORBEARANCE PAYMENTS

 

 (a) After the Companies pay the Forbearance Amount and Acceleration Payment in full, the Companies will be entitled, in its sole discretion, to buy out the Companies' continuing obligation to make Forbearance Payments to the Foundation (thereby terminating any further payment obligation in respect thereof) at the following time points with a one-time payment as set forth below. Such time points are to be calculated from the Effective Date.

i.
Period 1 (Effective Date through end of the fifteenth month following the Effectiver Date) Buyout = $200,000

 

ii.
Period 2 (the first day following the end of Period I through the end of the twenty-fourth month following the Effective Date)
Buyout= $500,000

 

iii.
Period 3 (the beginning of the third year following the Effective Date through the end of the fifth year following the Effective
Date) Buyout= $1,000,000

 

iv.
Period 4 (anytime after the beginning of the sixth year folJowing the Effective Date) Buyout= $2,000,000

 

(b) Any Buyout shall be paid by check or by wire transfer in United States dollars in Bethesda, Maryland, or at such other place and manner as the Foundation may designate in writing.

 (c) Any Buyout shall be paid in full, without deduction for any taxes or other fees imposed by any government or any transfer, collection, or similar charges; any such tax, fee, or charge shall be paid by the Companies.

 6. CSA PERFORMANCE AND FULL RELEASE

(a)
The Parties acknowledge that twenty-six (26) Additional Subjects should not have been enrolled in the Study based on the INCLUSION
CRITERIA AND EXCLUSION CRITERIA added via the Fourth Amendment to the CSA because these twenty-six (26) Additional Subjects were
Her2/neu+ overexpressors (IHC 3+ and/or positive FISH > 2.2). These twenty-six (26) Additional Subjects who were
Her2/neu+ overexpressors will be replaced with Her2/neu+ low expressors (IHC 1-2+ and/or positive FISH < 2.2 and>
1.2) in the Study, and will be AE37 randomized, at no additional charge to Antigen Express. These twenty-six (26) Additional Subjects
who were Her2/neu+ overexpressors will not count toward the Enrollment Maximum of three hundred thirty (330) subjects under the
CSA.

 

(b)
The Parties acknowledge that the Study Statement of Work clearly provides that the AE37 subtrial is part of a Master Efficacy
Trial that is conducted in concert with an evaluation of the GP2 vaccine. By combining the GP2 subtrial and AE37 subtrial under
the Master Efficacy Trial, costs for the trial infrastructure are shared and the control groups from the two subtrials may be
similar and merged thus reducing the overall mnnber of patients required for each subtrial to show statistical significance. For
the avoidance of doubt, the Parties acknowledge that the total number of patients includes this extended control group.

 

(c)
To the extent the Foundation may have suspended performance of any of its obligations under the CSA due to Antigen Express' failure
to make payments when due, the Foundation agrees to lift any such suspension of performance upon the full execution of this Agreement.

 

(d)
The Companies fully release and discharge Foundation, the Foundation’s employees, officers, directors, and agents, Institution,
and Institution's employees, officers, directors, and agents (collectively referred to as "Releasees") from any and
all claims and defenses, known and unknown, asserted or unasserted, which the Companies have or may have against Releasees as
of the date of the execution of this Agreement, including, but not limited to, any claim or defense based upon or related to (a)
or (b) above.

 

7.
TERMINATION

 

(a)
The Foundation may terminate this Agreement, in its sole discretion, in the circumstances set forth in this Section, and any such
termination shall be effective immediately upon the Foundation giving written notice to the Companies of any of the following:

 

i.
if the Companies do not make a payment due hereunder and fail to cure such non-payment (including the payment of interest in accordance
with this Agreement within thirty (30) days after the date of notice in writing of such non-payment by the Foundation;

 

ii.
if the Companies: are unable to pay their respective debts as such debts become due; makes a general assignment for the benefit
of creditors; has a petition in bankruptcy or a suit seeking reorganization, liquidation, dissolution, or similar relief filed
against it; or files or permits the filing of any petition or answer seeking to adjudicate itself bankrupt or insolvent, or seeking
for itself any liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or composition of the Companies
or their respective debts under any law relating to bankruptcy, insolvency, or reorganization or relief of debtors, or seeking
or consenting to the appointment of a trustee, custodian, receiver, liquidator or other similar official for the Companies or
for any substantial part of their property; or takes any corporate action to authorize any of the foregoing actions;

 

iii.
except as provided in subsections (i) and (ii) above, if the Companies default in the performance of any obligations under this
Agreement and the default has not been remedied within thirty (30) days after the date of notice in writing of such default by
the Foundation.

 

(b)
The termination of this Agreement shall not discharge the Parties from any obligation that it owes to another Party by reason
of any loss, cost, damage, expense, liability, or contractual duty that occurs or arises (or the circumstances, events, or basis
of which occurs or arises) prior to such termination, and shall not affect the right of the Parties to institute or maintain any
action for damages relating to any breach of this Agreement. It is the intent of the Parties that any such obligation owed by
a Party to the other Parties arising before the date of termination (whether the same shall be known or unknown at such date,
or whether the circumstances, events, or basis of the same shall be known or unknown at such date), including royalty obligations
(computed in accordance with Section 4) on sales made or ordered prior to the date of termination, shall survive the termination
of this Agreement.

 

 8. RELATIONSHIP BETWEEN THE PARTIES

Nothing
in this Agreement shall be deemed or construed to create a fiduciary relationship between the Companies and the Foundation.

9.
SUCCESSORS AND ASSIGNS

 

This
Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors, legal representatives,
and assigns.

 10. GOVERNING LAW

This
Agreement shall be governed by and interpreted in accordance with the Jaws of the State of Maryland without regard to principles
of conflict or choice of law. 

 11. NO WAIVER AND RESERVATION OF RIGHTS

Except
as expressly stated herein, nothing contained in this Agreement shall be construed as a waiver by Foundation of any provision
of the CSA and the Foundation hereby reserves all rights, privileges, and remedies granted nuder the CSA or applicable law.

In
addition, the observance of any term of this Agreement may be waived (whether generally or in a particular instance and either
retroactively or prospectively) by the Party entitled to enforce such term, but any such waiver will be effective only if in writing,
signed by the Party against which such waiver is to be asserted. Except as otherwise provided in this Agreement, no failure or
delay of a Party in exercising any power, right, or remedy under this Agreement will operate as a waiver thereof, nor will any
single or partial exercise of any such right, power, or remedy, preclude any other or further exercise thereof or the exercise
of any other right, power, or remedy. A waiver by a Party shall be limited to the specific instance in which it is given and,
therefore, any waiver by a Party of any obligation of another Party or breach by another Party of this Agreement or of any power,
right, or remedy of the waiving Party shall not be a waiver of any other obligation or further or future performance of the same
obligation, of any other or succeeding breach, of any other or further exercise of such power, right, or remedy or any other power,
right, or remedy.

 12. HEADINGS

The
section headings contained in this Agreement are for reference purposes only and are not intended to describe, interpret, define,
or limit the scope, extent, or intent of this Agreement.

13.
JOINT PARTICIPATION AND NEGOTIATION OF AGREEMENT

 

Each Party has had the opportunity to obtain the advice of legal counsel and to
review, comment upon, and negotiate this Agreement. Accordingly, it is agreed that no rule of construction shall apply against
any Party or in favor of any Party. This Agreement shall be construed in light of the fact that the Parties jointly prepared this
Agreement, and any uncertainty or ambiguity shall not be interpreted against any one Party and in favor of the other.

 14. COUNTERPART EXECUTION

This
Agreement and any modification or amendment thereof may be executed in counterparts, each of which shall be considered one and
the same agreement, and shall become effective when such counterparts have been signed by each of the Parties and delivered to
the other Parties.

 15. ENTIRE AGREEMENT; MODIFICATIONS

This
Agreement constitutes the complete agreement between the Parties concerning the subject matter hereof and replaces any prior oral
or written communications between the Parties. There are no conditions, understandings, agreements, representations, or warranties,
express or implied, that are not specified herein, and neither Party shall be obligated by any condition or representation other
than those expressly stated herein or as may be subsequently agreed by the Parties in writing. Any purported modification or amendment
of the express terms or provisions of this Agreement shall be effective only if contained in a written instrument signed by each
Party.

    	 	1	 

     

    

 

THE
PARTIES HAVE READ THIS AGREEMENT AND AGREE TO BE BOUND BY ALL TERMS AND CONDITIONS HEREIN.

IN
WITNESS WHEREOF, the Parties have entered into this FORBEARANCE AGREEMENT as of the Effective Date.

	ANTIGEN EXPRESS, INC.	 	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
	 	 	 
	By: /s/ James H. Anderson, Jr. M.D.	 	By: /s/ John W. Lowe
	Name: James H. Anderson, Jr. M.D.	 	Name: John W. Lowe
	Title: CEO	 	Title: President & CEO
	Date: 8 SEP 2013	 	Date: September 6, 2013
	 	 	 
	 	 	 
	GENEREX BIOTECHNOLOGY CORP.	 	 
	 	 	 
	By: /s/ Mark A. Fletcher	 	 
	Name: Mark A. Fletcher	 	 
	Title: President & CEO	 	 
	Date: 9 SEP 13	 	 

    	 	2LICENSE
AND RESEARCH AGREEMENT

BETWEEN 

ANTIGEN
EXPRESS, INC.

(A
WHOLLY-OWNED SUBSIDIARY OF

GENEREX
BIOTECHNOLOGY CORPORATION)

 

AND

 

SHENZHEN
BIOSCIEN PHARMACEUTICALS CO. LTD.

November
29th, 2017

 

 

 

 

 

 

    	 	1	 

     

    

 

TABLE
OF CONTENTS

 

    	 	2	 

     

    

    	 	3	 

     

    

 

    	 	4	 

     

    

LICENSE
AND RESEARCH AGREEMENT

This
License and Research Agreement (the "Agreement"), effective as of the day of November, 2017 (the "Effective
Date"), is by and between Antigen Express, Inc., a wholly-owned subsidiary of Generex Biotechnology Corporation,
a Delaware corporation, with an address of 4145 North Service Road, Suite 200, Burlington, Ontario, Canada L7L 6A3 (hereinafter
referred as "Licensor"), and Shenzhen BioScien Pharmaceuticals Co., Ltd., located at Room 311, First Building,
Shenzhen Overseas Venture Park (Longgang), Shenzhen 518116, Guangdong, China (hereinafter referred to as "Licensee").
Licensor and Licensee may each be referred to herein individually as a "Party" and collectively

RECITALS

WHEREAS,
Licensor is a publicly-traded biotechnology company (OTCPink:GNBT) managed by an executive management team and governed by
the Board of Directors (the

“Board”);

 

WHEREAS,
the executive management team is responsible for all matters relating to patent administration and technology transfer applicable
to Licensor, and is expressly authorized to negotiate and execute this Agreement;

 

WHEREAS,
Licensor is (or in the future, may be) the owner of certain patent rights, other intellectual property rights, know-how and
other proprietary rights in the Territory relating to Licensed Compounds and/or Research Information (as each of these capitalized
terms is defined herein);

 

WHEREAS,
Licensor desires to grant to Licensee an exclusive license in the Field (as defined below) in the Territory (as defined below)
related to the Licensed Compounds and Research Information;

 

WHEREAS,
Licensee desires to research and develop Licensed Compounds, Research Information and Licensed Products, and to commercialize
Licensed Products, in the Field in the Territory;

 

WHEREAS,
Licensor and Licensee wish to enter into this Agreement to enable Licensee to further develop and commercialize Licensed Products
that incorporate or use one or more compounds within the Licensed Compounds and/or the Research Information, and to enable Licensee
to use and exploit in the Field in the Territory any information, technology or intellectual property that relates to Licensed
Compounds or Research Information, or that covers Research Inventions.

 

NOW
THEREFORE, in consideration of the premises and mutual covenants set forth below and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.
DEFINITIONS

For
the purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires: (a) references
to "Articles," "Sections" and other subdivisions, and to "Exhibits," shall refer to articles, sections,
subdivisions and exhibits of this Agreement, unless specified to be referring to another agreement between the Parties; (b) the
use of the term "including" shall mean "including without limitation"; (c) the words "herein," "hereof,"
"hereunder" and other words of similar import refer to this Agreement as a whole, and not to any particular provision;
(d) the use of the phrase "by Licensor," "by Licensee" or "by a Party" shall mean "by such
Party (and/or on behalf of such Party)"; and (e) the following initially capitalized terms in this Agreement, whether used
in the singular or plural, shall have the following meanings:

 

1.1
Affiliate

Any
Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control
with the designated Party, but only for so long as such relationship exists. For the purposes of this definition, "control"
means (a) in the case of corporate entities, ownership of fifty percent (50%) or more of the outstanding shares of stock entitled
to vote for directors of such corporation, or (b) in the case of non-corporate entities, direct or indirect ownership of fifty
percent (50%) or more of the equity interest with the power to direct the management and policies of such non-corporate entities,
or (c) the possession, directly or indirectly, of such other power to direct or cause the direction of the management and policies
of any Person, whether through the ownership of voting securities, by contract, or otherwise.

 

1.3
Approved Sale

The
sale of a Licensed Product for human pharmaceutical use in the Territorys.

 

1.4
AE37

Peptide
name: AE37 (li-Key/HER2/neu776-790)

 

Trade
name: AE37

 

Appearance:
White lyophilized powder 91'1

 

Peptide
sequence: AC-LRMKGVGSPYVSRLLGICL-NH2

 

Molecular
Weight: 1052.6 daltons

 

Peptide
counter ion: Acetate

 

AE37
means the hybrid HER2/neu peptide AE37 (li-Key/HER2/neu776-790), a fifteen amino-acid peptide to which the four amino-acid sequence
LRMK has been added and it is produced by solid-phase peptide synthesis. The AE37 peptide is manufactured, purified by High Performance
Liquid Chromatography (HPLC), and lyophilized in an acetic acid and acetonitrile solution. The drug substance is stored as a lyophilized
powder as per Good Manufacturing Practices (GMP) including in-process, drug substance and finished drug substance testing of AE37;
testing includes appearance, purity by HPLC and mass spectral analysis, identification by amino acid content and sequence, and
quality by bioburden, sterility USP and endotoxin. The peptide is purified to ¥95 0,/0 purity. Residual organic volatiles,
counter ion content, water content and non-peptide content (by AA) are also routinely determined. The drug substance is lyophilized
and frozen at -20 oc and the bulk drug substance is provided as per clinical protocol requirements.

Manufacturer
(Drug Substance and Drug Product) of AE37 AE37 

PolyPeptide
Laboratories San Diego

9395
Cabot Drive

San
Diego, CA 92126 USA

 

1.5
Change of Control

With
respect to a Party, a "Change of Control" of such Party shall mean (a) a sale or conveyance of all or substantially
all of the assets of such Party to which this Agreement relates; (b) a consolidation, merger or reorganization of such Party with
or into any other company, limited liability company or other entity (other than a wholly-owned subsidiary of such Party) or other
transaction or series of transactions in which the stockholders of such Party immediately prior to the transaction fail to own
fifty percent (50%) or more of the voting stock of the surviving company following the transaction (taking into account only stock
of the company held by such stockholders prior to the transaction); or (c) an acquisition of shares from such Party or an Affiliate
or from the stockholders of such Party or an Affiliate immediately prior to such acquisition as a result of which a third party
or group of third parties acquires control, directly or indirectly, of fifty percent (50%) or more of the voting stock of such
Party following such acquisition.

 

1.6
China

 

The
People's Republic of China (PRC), including the Hong Kong Special Administrative Region of the PRC, Taiwan and the Macau Special
Administrative Region of the PRC.

 

1.7
Collaboration

 

Two
or more affiliates (including Licensor and Licensee) work together to realize or achieve the drug development and commercialization
successfully. For example, the collaboration will be established with a major pharmaceutical company to perform the combination
therapeutic clinical trials.

 

1.8
Combination Therapy

 

Two
or more medications combined and used to treat one disease. For example, AE37 combined with a checkpoint inhibitor for the treatment
of prostate cancer.

 

1.9
Confidential Information

 

Any
and all non-public information that is disclosed by a Party (the "Disclosing Party") to the other Party (the "Receiving
Party") is in connection with this Agreement. For the sake of clarity, the Parties acknowledge that a Disclosing Party may
or may not be the c».mer of such disclosed information (for example, if one Party discloses to the other Party any Confidential
Information that is jointly owned hereunder, such disclosure does not render such Confidential Information solely owned by the
Disclosing Party, but such information remains Confidential Information). Disclosures by a Party's Affiliate shall be deemed disclosures
by that Party, and disclosures to a Party's Affiliate shall be deemed disclosures to that Party. Notwithstanding the foregoing,
Confidential Information shall not include any part of such information that:

1.9.1
Was already known to the Receiving Party without access to or use of Confidential Information of the Disclosing Party, as evidenced
by the Receiving Party's written records;

1.9.2
Was generally available to the public or was otherwise part of the public domain at the time of disclosure hereunder to the Receiving
Party;

1.9.3
Became generally available to the public or otherwise becomes part of the public domain after disclosure hereunder to the Receiving
Party, and other than through any act or omission of the Receiving Party in breach of this Agreement;

1.9.4
Was subsequently lawfully disclosed to the Receiving Party by a third party on a non-confidential basis, other than in breach
of a confidentiality obligation of such third party to the Disclosing Party or any other third party; or

1.9.5
Was developed or discovered by the Receiving Party or its Affiliates without access to or use of Confidential Information of the
Disclosing Party, as evidenced by the written records or communications of either Party.

 

1.10
Control(s) or Controlled

 

With
respect to any (a) item of information, including Research Information and Technical Information, or (b) intellectual property
right, the possession (whether by ownership, license or otherwise, but other than pursuant to this Agreement) by a Party of the
lawful and contractual ability to disclose to the other Party, or to grant to the other Party access and/or a license to or under,
such item of information or intellectual property right within the scope of this Agreement, without the obligation to pay' royalties
or other consideration to any third party.

1.11
Dollars

 

United
States Dollars, or the lawful currency of the United States of America.

1.12
Field

 

The
Field is restricted to preventative, palliative and other therapeutic uses and applications of the Licensed Compound, the Research
Information, and the Licensed Product for the immunotherapeutic treatment of prostate cancer.

1.13
Government Authorization

 

Any
consent, license, registration or permit issued, granted, given or otherwise made available by or under the authority of any Governmental
Body or pursuant to any law, regulation, or ordinance.

 

1.14
Governmental Body

 

1.14.1
nation, state, county, city, town, borough, village, district or other jurisdiction;

1.14.2
federal, state, local, municipal, foreign or other government;

1.14.3
governmental or quasi-governmental authority of any nature (including any agency, branch, department, board, commission, court,
tribunal or other entity exercising governmental or quasi-governmental powers);

 

1.14.4
multi-national organization or body

 

1.14.5
body exercising, or entitled or purporting to exercise, any administrative, executive, judicial, legislative, police, regulatory
or taxing authority or power; or

 

1.14.6
official of any of the foregoing

 

1.16
Licensed Compounds

 

AE37
and all its associated compounds in the patent, as immunotherapy for prostate cancer, that are owned or controlled by Licensor.

 

1.17
Licensed Know-How

 

Any
and all know-how, trade secret or other intellectual property rights (including rights in Research Information and Technical Information,
but excluding Licensed Patent Rights and other rights to patents or patent applications) owned or Controlled by Licensor, as of
the Effective Date or at any time during the term of this Agreement, and relating to the use and/or exploitation of Licensed Compounds,
Research Information and/or Licensed Products in the Field; provided that the term "Licensed Know-How" shall expressly
exclude: a) know-how, trade secret and other intellectual property rights related to any active pharmaceutical ingredient in a
Combination Product that is not itself a Licensed Product; b) know-how, trade secret and other intellectual property rights related
to AE37 that are outside the Field.

 

1.18
Licensed Patent Rights

 

(a)
Any and all patents and provisional and non-provisional patent applications set forth in Exhibit A attached hereto;
and (b) any and all other patents and patent applications owned or Controlled by Licensor anywhere in the Territory, as of
the Effective Date or at any time during the term Of this Agreement, containing one or more Claims to, or otherwise covenng,
any Licensed Compound or Research Information; including any and all renewals, divisions, continuations and
continuations-in-part Of any Of the foregoing, any and all patents issued thereon, and any reissues, reexamination,
extensions, substitutions, confirmations, registrations, revalidations, revisions and additions Of or to such patents, and
any and all foreign counterparts anywhere in the TetTitory Of any Of the foregoing.

 

1.19
Licensed Product

 

Any
formulations Of a final Drug Product, as defined by the U.S. FDA, Of AE37 immunotherapy for prostate cancer that
is manufactured under standards established by Regulatory Authorities for commercial sale in the Territory in the
Field.

 

1.20
NDA

 

New
Drug Application filed with the Food and Drug Administration Of the United States or any successor agency thereto (“FDA")
and the Chinese Food and Drug Administration (“CFDA').

 

1.21
Net sales

 

With
respect to a Licensed product, the aggregate gross invoice prices charged for sales Of such Licensed Product to third parties
by Licensee and its Affiliates and Sub-licensees after deducting, if not previously deducted from the amount invoiced or received
for sales Of Licensed Products:

 

1.21.1
reasonable and customary trade, quantity, and cash discounts actually given, as well as discounts, rebates or governmentally mandated
payments, to the extent actually allowed and taken;

1.21.2
returns, rebates, chargebacks and other allowances actually given; iß*h,

 

1.21.3
retroactive price reductions that are actually granted;

 

1.21.4
to the extent separately stated on the relevant invoices, actual transportation and insurance costs incidental to sales of Licensed
Products; and

 

1.21.5
taxes, tariffs, customs duties and surcharges and other governmental charges (other than income taxes) incurred in connection
with the sale, exportation, or importation of Licensed Products.

In
the event that a Licensed Product is sold in the form of a combination product containing one or more active pharmaceutical ingredients
which are themselves not Licensed Products (a "Combination Product"), the Net Sales attributable to the Licensed Product
portion of such Combination Product, for the purposes of determining royalty payments hereunder, shall be determined by multiplying
the Net Sales of the Combination Product, during the applicable Royalty Reporting Period, by the fraction A/(A+B), where A is
the average sales price of the Licensed Product when sold separately in finished form, and B is the sum of the average sales prices
of each of the other active pharmaceutical ingredients included in the Combination Product when sold separately in finished form,
in each case during the applicable Royalty Reporting Period or, if sales of both the Licensed Product and the other active pharmaceutical
ingredients included in the Combination Product did not occur in such period, then in the most recent Royalty Reporting Period
in which sales of both occurred. In the event that such average sales price cannot be determined for both the Licensed Product
and all other active pharmaceutical ingredients included in the Combination Product, Net Sales attributable to the Licensed Product
portion of such Combination Product for the purposes of determining royalty payments hereunder shall be calculated by multiplying
the Net Sales of the Combination Product by the fraction C/(C+D), where C is the fully absorbed cost of the Licensed Product (exclusive
of royalties, milestone payments or similar costs and payments to a third party(ies)), and D is the sum of the fully absorbed
cost of each other active pharmaceutical ingredient(s)included in the Combination Product (which fully absorbed cost of the other
active pharmaceutical ingredient(s) included in the Combination Product shall exclude any royalties, milestone payments, and similar
costs and payments to a third party(ies)).

 

Sales
Of Licensed Product among Licensee, its Affiliates and Sub-licensees for resale by Licensee, its Affiliate(s) or Sub-licensee(s)
shall not be considered a sale of Licensed product, but the resale by Licensee or such Affiliate(s) or Sub-licensee(s) to a third
party shall be a sale of Licensed Product.

 

Licensee
shall have the right to distribute or make available commercially reasonable quantities Of Licensed Products free of charge for
use in clinical studies, for charitable purposes, and for use as commercial samples.

1.22
Non-Affiliate Acquirer

 

Any
Person that is not an Affiliate of Licensee and that no officer, director or stockholder of Licensee or group thereof Controls
(where "Control" is defined as in the definition of "Affiliate' except that the relevant percentage shall be five
percent (5%) instead of percent (50%).

 

1.23
Person

 

An
individual, partnership, corporation, business trust, limited liability company, limited liability partnership, joint stock company,
trust, unincorporated association, joint、venture or other entity or a Governmental Body.

 

1.24
Phase I Clinical Study 第 I 期临床研宄

 

A
controlled clinical study in humans of a Licensed Product that is conducted in accordance with FDA guidelines for conduct ofa
Phase I clinical study to evaluate the safety (dose range) of the Licensed Product, and to determine the dose range of the Licensed
Product, which clinical study is typically well controlled and closely monitored and intended to obtain statistical significance.

 

1.25
Phase II Clinical Study

 

A
controlled clinical study in humans of a Licensed Product that is conducted in accordance with FDA guidelines for conduct of a
Phase Il clinical study to evaluate the effectiveness of the Licensed Product for a particular indication or indications in patients
with the disease or condition under study, and to determine the common short-term side effects and risks associated with the Licensed
Product, which clinical study is typically well controlled and closely monitored and intended to obtain statistical significance.

1.26
Phase II Clinical Study

 

An
expanded controlled and/or uncontrolled clinical study in humans of a Licensed Product that is performed after preliminary evidence
from Phase Il studies suggesting effectiveness of the Licensed Product has been obtained, which study is intended to gather additional
information about Licensed Product effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of
the Licensed Product, and to provide an adequate basis for physician labeling. Phase Ill Clinical Studies are used to support
an application for Regulatory Approval submitted to a Regulatory Authority in the Territory.

 

1.27
Regulatory Approval

 

The
approval or authorization (including the approval of an NDA, where applicable) by any Regulatory Authority in the Territory that
is necessary for the import, manufacturing, distribution, marketing, promotion, and sale of Licensed Product(s) in the Territory.

 

1.28
Regulatory Authority

 

China
Food and Drug Administration (CFDA).

 

1.29
Research Inormation

 

All
information developed or generated by Licensor in respect of the Licensed Compounds, including Research Inventions, technical
information and data, pre-clinical and clinical information and data, process and product information, formulas, formulations,
compositions, materials (including biological and chemical materials), devices, research information and data, manufacturing information
and data, computer programs, test results, business plans, accounting records, research and development reports, supplier information,
marketing and sales information, other business and financial information, trade secrets and know-how, and any record of the above,
including writings, computer records and programs, photographic films, drawings, illustrations, pictures, video recordings, audio
recordings, models and samples.

 

1.30
Research Inventions

 

Any
inventions or improvements (whether or not patentable) conceived, reduced to practice, made, developed or generated by Licensor
others working under Licensor's direction or control.

 

1.31
Sub-license Agreement

 

An
agreement between Licensee and a Sub-licensee that complies with the provisions and requirements of Section 3.3 below.

1.32
Sub-licensee

 

Any
Person to which Licensee shall have granted a sublicense of the rights granted to Licensee by Licensor hereunder.

 

1.33
Technical Information

 

All
information (including all Confidential Information of Licensor, data, materials, devices, research reagents and results, formulas,
drawings, samples, processes, designs, submitted manuscripts, draft manuscripts, information contained in laboratory notebooks
and records, process information, clinical protocols and results, and other information and know-how) pertaining to the isolation,
identification, synthesis, manufacture or use of a Licensed Compound, a Research Invention and/or a Licensed Product (but expressly
excluding information related to any active pharmaceutical ingredient in a Combination Product that is not itself a Licensed Product)
in the Field (a) that is owned or Controlled by Licensor as of the Effective Date; or (b) that Licensor comes to own or Control
at any time during the term of this Agreeme0nt independent from, and not in connection with or in the course of performing under,
this Agreement. The term "Technical Information" shall expressly exclude Research Information.

 

1.34
Territory

 

China
(including mainland, Taiwan, Hong Kong and Macau.

 

1.35
Additional Definitions

	Defined
    Term	 	Section
    in which Defined
	 	 	 
	 Antigen
    Express	 	 Preamble
	 Agreement	 	 Preamble
	 CDA	 	 5.1
	Combination
    product	 	1.23.5
	Board	 	Recitals
	Common
    Stock	 	 
	Competitive
    Product	 	4.2.4(a)
	Disclosing
    Party	 	1.9
	Effective
    Date	 	Preamble
	 	 	 
	FDA	 	1.22
	Heads	 	14.10.2
	 	 	 
	Licensee	 	Preamble
	Licensee
    Indemnitee	 	10.2
	Licensor	 	Preamble
	Licensor
    Indemnitee	 	10.1
	Losses	 	10.1
	Note	 	 
	Panel	 	14.10.3
	Party/Parties	 	Preamble
	Proposed
    Public Disclosure	 	5.6
	Purchase
    Agreement	 	Recitals
	Receiving
    Party	 	1.9
	Research
    Term	 	 
	Royalty
    Reporting Period	 	4.2.6
	Securities	 	 
	Shortfall
    Payment	 	3.4
	Third-Party
    Claim	 	7.3

 

2.
RIGHTS AND RESPONSIBILITIES

2.1
Licensee

 

The
Licensee and its Sub-licensee have the same rights that are granted by the Licensor described in this Agreement in performing
the research, development, production of the Licensed Compounds for product, product commercialization and distribution in the
Field in the Territory. In order to accelerate the process of drug development, the Licensee and its Sub-licensee can chose the
best suitable country or area outside of the Territory to conduct the clinical trials including establishment of global multi-center
clinic trial. The Licensee will provide 100% of the funding to support the clinical development and commercialization of Licensed
Compounds, alone and in combination therapy, in the Territory, including, without limitation, funding of the Phase I Clinical
Study, the Phase Il Clinical Study and the Phase Ill Clinical Study for the treatment of prostate cancer, which will be conducted
in compliance with ICH guidelines. The Licensee is responsible for obtaining the Regulatory Approval from the Chinese Food and
Drug Administration ("CFDA") for the Licensed Compounds as monotherapy and/or combination therapy for the immunotherapeutic
treatment of prostate cancer in the Territory. The Licensee agrees to provide 100% of the funding required to manufacture, market,
sell, and distribute the Licensed Compounds for the Field in the Territory. The Licensee has the right to file New Drug Applications
(NDA) and to file Marketing Authorization Applications (MAA) with the CFDA and has the right to produce the product in the Territory.

2.2
Licensor

 

Subject
to compliance by the Licensee with its funding and other obligations under this Agreement, the Licensor shall support the research,
development and commercialization of the Licensed Compounds to be performed by Licensee in the Territory. The support from the
Licensor includes, but is not limited to, sharing study data and information and providing various consulting, operational and
management strategies. The Licensor shall ensure compliance by Antigen Express, Inc. with its obligations under the Clinical Trial
Collaboration and Supply Agreement with Merck Sharp & Dohme B.V. dated June 28, 2017 in respect of a combination therapy (AE37+check
point inhibitor) for breast cancer.

  

The
Licensor will provide the Licensee with all documentations, materials, and files to support the applications for certificates
for all clinical trials and New Drug Application (NDA) and to file Marketing Authorization Application (MAA) in the Territory,
all as contemplated by this Agreement. The Licensor shall provide reasonable cooperation to the Licensee in respect of the clinical
studies in the Territory required by this Agreement.

3.
LICENSE AND SUB-LICENSES

3.1
Exclusive License Granted to Licensee

 

Subject
to the terms and conditions of this Agreement, Licensor hereby grants to Licensee, and Licensee accepts, an exclusive (even as
to Licensor and its Affiliates), royalty-bearing license, including the right to grant sub-licenses through multiple tiers of
sub-licensing (subject to Section 3.3 below), under Licensed Know-How and Licensed Patent Rights, to make, have made, use and
import Licensed Compounds, Research Information and Licensed Products, and to produce, distribute, promote, market, sell and offer
for sale Licensed Products, in the Field in the Territory.

 

3.2
Retained Rights of Licensor

 

Notwithstanding
anything to the contrary in Section 3.1, Licensor and its Affiliates retain the right to use and practice the Licensed Know-How
and Licensed Patent Rights: (a) for development and commercialization of Licensed Compounds, Research Information and/or Licensed
Products in the Field, either themselves, or with or for the benefit of a third party, globally, except in the Territory; and
(b) for research, teaching and educational purposes (excluding research and/or development of Licensed Compounds, Research Information
and Licensed Products for use and/or exploitation in the Field in the Territory on behalf of any Person other than Licensee or
its Affiliates). Licensee shall not utilize the Licensed Compounds, Licensed Know-How, Licensed Patent Rights, Research Information,
Research Inventions, or Technical Information for any purpose other than the production, distribution, and sale of Licensed Products
in the Field in the Territory in accordance with this Agreement.

 

3.3
Sub-licenses Granted by Licensee

 

Each
Sub-license Agreement executed by Licensee or any Sub-licensee shall be subject and subordinate to the terms and conditions of
this Agreement, and shall contain terms and conditions consistent with those in this Agreement, sufficient to enable Licensee
to comply with this Agreement and requiring the Sub-licensee to comply with the relevant terms and conditions of this Agreement,
including this Section 3.3 and Sections 4.22, 4.2.5, 4.2.6, 9.1 and 10.5, and Article 5. Subject to Licensor's obligations set
forth in Article 5, Licensee shall provide Licensor with an accurate and complete copy of any Sub-license Agreement within seven
(7) days of entering into such Sub-license Agreement. Unless otherwise agreed in writing by Licensor, any sub-license of the rights
granted under Section 2.1 shall terminate on any termination or expiration of this Agreement.

3.4
Diligence Obligations

 

During
the term of this Agreement, Licensee shall use commercially reasonable efforts to develop and commercialize Licensed Products
in the Territory, either itself or through its Affiliates and Sub-licensees. To that end, Licensee agrees to provide Licensor
with a detailed time & events schedule (the "Timeline") for the commercial development of the Licensed Products
in the Field in the Territory. Licensor reserves the right to review and approve the Timeline to ensure the global regulatory
and commercial integrity of the development program. Without limiting the generality of the foregoing, beginning eighteen (18)
months from the Effective Date, Licensee (itself or through its Affiliates and/or Sub-licensees) shall initiate the Phase Il Clinical
Study in the Field. Licensee agrees to expend a minimum of Five Hundred Thousand United States Dollars ($500,000 USD) during this
18 month period to complete the regulatory requirements for chemistry, manufacturing & control (CMC), toxicology, and a Phase
I Clinical Study necessary to initiate the Phase Il Clinical Study. From the initiation of a Phase Il Clinical Study, and for
three (3) years thereafter, Licensee agrees to expend a minimum of Five Hundred Thousand United States Dollars ($500,000 USD)
annually toward the clinical development of the Licensed Products in the Field in the Territory, with an understanding that a
Phase Ill Clinical Study will be initiated at the end of this 3-year period. Thereafter, and until the commercial launch of Licensed
Products in the Field in the Territory, Licensee agrees to expend a minimum of One Million United States Dollars ($1,000,000 USD)
annually to complete the Phase Ill Clinical Study, regulatory submissions, and other product development activities required by
the CFDA for regulatory approval and commercialization of the Licensed Products in the Field in the Territory.

 

Each
six (6) months, Licensee shall provide Licensor with a comprehensive and detailed written report summarizing its efforts under
this Section 3.4 in the prior six (6) month period, comprising of a listing of research and development activities. The report
will include a progress report, with any updates to the Timeline for key events in the research and development of Licensed Products
in the Field in the Territory.

 

Licensee
agrees to share all clinical data and reports with Licensor to support the submission of global regulatory filings regarding the
safety and efficacy of the Licensed Products.

 

In
the event that Licensee fails to expend the monetary amount set forth in this Section 3.4 in any given 12-month period, Licensee
may cure such default by paying to Licensee the difference between the agreed-upon amount, and the amount actually expended by
Licensee in that 12-month period ("Shortfall Payment"); provided that such Shortfall Payment shall be delivered within
thirty (30) days after Licensee is required to deliver the WTitten report evidencing such default. If Licensee fails to cure such
default by making such Shortfall Payment, Licensor shall have the right to either terminate this Agreement, including the licenses
granted hereunder, or convert the exclusive licenses granted in Section 3.1 to non-exclusive licenses, by written notice to Licensee.
In the event that any dispute arises under this Section

3.4,
such dispute shall be resolved in accordance with Section 14.10.

 

3.5
Reservation of Rights

 

Licensor
reserves all rights not expressly granted in this Agreement, and no rights or licenses are granted in this Agreement except as
expressly set forth herein, whether by implication, estoppel or otherwise.

4.
PAYMENTS, ROYALTIES AND STOCK

In
consideration for the license rights and other rights granted by Licensor to Licensee under this Agreement, on the date of execution
of this Agreement, Licensee shall pay to Licensor a non-refundable, non-creditable upfront payment of Seven Hundred Thousand United
States Dollars ($700,000 USD), by wire transfer to the Licensor account designated in Exhibit B annexed hereto. In addition, in
consideration for the license rights and other rights granted by Licensor to Licensee under this Agreement, Licensee shall pay
the following milestone payments to Licensor, upon achievement of the corresponding milestone events:

4.1
Milestone Payments

 

4.1.1
Upon achievement of the recited milestone events by the Licensee, Licensee shall pay the following milestone payments to Licensor:

(a)
One Million United States Dollars ($1,000,000) USD, upon completion of the Phase Il Clinical Study of a Licensed Product in the
Territory as defined by locking of the applicable clinical study database;

 

(b)
One Million United States Dollars ($1,000,000 USD), upon completion of the Phase Ill Clinical Study of a Licensed Product in the
Territory as defined by locking of the applicable clinical study database;

 

(c)
Two Million United States Dollars ($2,000,000 USD), upon first NDA or MAA (or equivalent) approval in the Territory in respect
of a Licensed Product.

 

4.1.2
Licensor shall be notified by the Licensee promptly upon achievement any of the above-specified milestone events, and Licensee
shall pay Licensor the specified corresponding milestone payment within thirty (30) days after achieving the applicable milestone
event.

4.2
Royalties

 

4.2.
I Subject to Sections 4.2.2, 4.2.3 and 4.2.4, as further consideration for the license rights granted to Licensee under this Agreement,
and in addition to any milestone payments payable to Licensor pursuant to Section 4.1, during the term of this Agreement Licensee
shall pay to Licensor an intellectual property royalty payment in an amount equal to Ten Percent (10%) of Net Sales within the
Territory of Licensed Products. The Parties acknowledge and agree that the royalty rates and structure set forth in this Section
4.2 (including the reduction in royalty rates provided for herein) (a) have been adopted after good faith negotiation and for
the convenience of the Parties; and (b) are payable whether or not a Licensed Product is covered by Licensed Patent Rights.

4.2.2
Notwithstanding anything to the contrary in this Section 4.2, Licensee shall have no obligation to pay royalties to Licensor on
sales of Licensed Products between Licensee and its Affiliates or Sub-licensees, where such Licensed Products will be resold to
an unrelated third party; provided that, in such instances, the obligation to pay royalties hereunder shall arise upon the sale
(or resale) of Licensed Products by Licensee's Affiliate or Sub-licensee to unrelated third parties. If, however, Licensee's Affiliate
or Sub-licensee is the commercial end user of such Licensed Products (for uses other than research, development or testing purposes),
then royalties shall be due hereunder on the greater of (a) Licensee's Net Sales resulting from Licensee's sale of such Licensed
Products to such

Affiliate
or Sub-licensee, and (b) Net Sales determined using the average sales price of Licensed Products in arms' length sales to unrelated
third parties during the current Royalty Reporting Period or, if there were no such sales during such Royalty Reporting Period,
during the most recent Royalty Reporting Period when there were such sales.

 

4.2.3
In the event that Licensee is obligated to pay a royalty under one or more third-party license agreements with respect to a Licensed
Compound component of a Licensed Product, then Licensee may reduce the royalty rate payable to Licensor (as set forth in Section
4.2.1) by an amount equal to one-half the total royalties payable to such third-party licensors; provided, however, that application
of this Section 4.2.3 shall not reduce the royalty rate payable by Licensee to less than Four Percent (4.0%).

 

4.2.4
Upon:

 

(a)     
the date of first Approved Sale in the Territory of a Competitive Product (wherein the term "Competitive Product" is
defined as any product containing as an active pharmaceutical ingredient one or more Licensed Compounds, which product is has
the same pharmaceutical purpose as a Licensed Product) or a generic version of a Licensed Product, if a Licensed Product was covered
by Licensed Patent Rights in the Territory at or prior to the time of such Competitive Product Approved Sale, but is no longer
covered by Licensed Patent Rights (whether due to expiration, abandonment, a final, Lin-appealable adjudication of invalidity
or otherwise); or

(b)    
the date of first Approved Sale of a Competitive Product in the Territory, if a Licensed Product was not covered by Licensed Patent
Rights in such country at or prior to the time of such sale;

 

the
royalty rate payable by Licensee with respect to such Licensed Product shall be reduced to Four Percent (4.0%), unless and until
such Licensed Product shall subsequently be covered by Licensed Patent Rights in the Territory.

4.2.5
Licensee shall keep, and shall obligate each of its Affiliates and Sub-licensees, if any, to keep, full and accurate books of
account containing all particulars that are reasonably necessary for the purpose of calculating the royalties and other amounts
payable by Licensee to Licensor hereunder. Without limiting the foregoing sentence, Licensee shall keep full and accurate records
of gross sales revenues from and Net Sales of Licensed Products. Such books, records and pertinent supporting data of Licensee,
its Affiliates and Sub-licensees that are necessary to verify the payment of royalties and other amounts in compliance with this
Agreement shall be available for inspection by Licensor during normal business hours of Licensee, for three (3) years following
the end of the calendar half year to which they pertain (but Licensor may not perform such inspection more than once per twelve
(12)-month period). Any such inspection shall be performed by an independent certified public accountant retained by Licensor
(and reasonably acceptable to Licensee) for the sole purpose of verifying reports and payments by Licensee hereunder.

4.2.6
Within six (6) months after the first day of January and July of each year during the term of this Agreement (including the first
day of the half year following the expiration or termination of this Agreement), and beginning after the first commercial sale
of a Licensed Product in the Territory, Licensee shall deliver to Licensor a true and accurate reports of any royalty amounts
payable to Licensor under this Agreement in relation to Net Sales made by or reported to Licensee in the preceding calendar half
year (the "Royalty Reporting Period"), as well as other information that is pertinent to calculation of such royalties
(e.g., a report due on May 31 shall pertain to the preceding period January I through March 31). Licensee shall require its Affiliates
and Sub-licensee to report to Licensee information as reasonably necessary to comply with Licensee's obligations under this Agreement.
These reports shall include at least the following:

(a)     
the calendar half year period covered by the report;

 

(b)    
a description of each Licensed Product sold by Licensee, and each Licensed Product sale reported to Licensee by its Affiliates
and Sub-licensees, during such calendar half year;

 

(c)     
the total quantity of each Licensed Product sold by Licensee, and each Licensed Product sale reported to Licensee by its Affiliates
and Sub-licensees, during such calendar half year, by country (or by region, but only if regional reporting is consistent with
the Net Sales information kept by Licensee in its normal course of business);

(d)    
gross sales revenues, deductions from gross sales and Net Sales made or reported during such calendar half year, by Licensed Product
and by country (or by region, but only if regional reporting is consistent with the Net Sales information kept by Licensee in
its normal course of business);

(e)     
names and addresses of all Affiliates and Sub-licensees of Licensee involved in the distribution or sale of Licensed Products
in such calendar half year, if Licensee has not previously provided such information to Licensor; and

(f)      
total royalties payable to Licensor for such calendar half year.

4.2.7
Simultaneously with the delivery of each half year royalty report, Licensee shall pay to Licensor the royalty calculated for the
Royalty Reporting Period covered by such report. If no royalties are due, it shall be so reported by Licensee. Each such royalty
payment shall be made in Dollars by wire transfer of immediately available funds to the Licensor account designated Exhibit B
annexed hereto (or such other account as may be designed in writing by the Licensor from time-to-time). In the event that conversion
from any foreign currency shall be required, such conversion shall be at the average rate of exchange published in The Wall Street
Journal for the calendar half year to which the payment pertains. Any amount not paid when due hereunder shall accrue interest
at the lesser of one and one-half percent (l .5%) or the maximum rate allowed by law.

4.3
Withholding of Taxes

 

Each
Party shall comply with applicable tax authority guidelines regarding filing and reporting for income tax purposes. Neither Party
shall treat their relationship under this Agreement as a partnership or as a pass-through entity for tax purposes. Licensee shall
be responsible for and shall collect all governmental and regulatory sales and other taxes, charges, duties and fees that are
due and owing upon sales of Licensed Products by Licensee and its Affiliates and Sub-licensees to third parties, excluding taxes
on Licensor's net income. Any withholding taxes shall be paid by Licensee at the rate(s) required by applicable law, and shall
be paid to the appropriate fiscal or tax authorities on behalf of Licensor. Licensee shall promptly provide to Licensor receipts
from the government or taxing authority evidencing payment of such taxes, if available, or other proof of payment if official
receipts are not available, and shall provide reasonable assistance to Licensor to obtain tax credits therefor. To the extent
Licensor actually uses any such tax credits for withholding taxes, as determined by it in its reasonable discretion, Licensor
shall refund to Licensee the amount of such credits used; provided that Licensor shall not be required to refund any payment of
such withholding tax to Licensee to the extent such payment would result in Licensor being in a worse after-tax economic position
(as determined by Licensor in its reasonable judgment) than if such withholding tax had never been imposed.

5.
CONFIDENTIALITY; PUBLICATION

Licensee
shall ensure that its employees and those of its Affiliates and Sub-licensees who have access to any Technical Information of
Licensor agree in writing to be bound by appropriate confidentiality and non-use obligations which are no less stringent than
those imposed on Licensee hereunder.

5.1
Confidential Information

 

Except
to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in writing, each Party shall treat Confidential
Information of the other Party in accordance with that certain Confidential Disclosure Agreement by and among the Parties (the
"CDA") dated as of the I st day of September, 2016.

 

5.2
Permitted Disclosures

 

Notwithstanding
the foregoing Section 5.1, the Receiving Party may disclose Confidential Information of the Disclosing Party, and Licensee may
disclose Technical Information to the extent such disclosure is reasonably necessary to:

5.2.1
file or prosecute patent applications, or in connection with patent interferences or patent oppositions, as contemplated by this
Agreement;

 

5.2.2
prosecute or defend litigation, as contemplated by this Agreement;

 

5.2.3
file documents required by applicable law, including filings with the U.S. Securities and Exchange Commission and comparable governmental
agencies applicable to the Parties, with tax authorities, and with Regulatory Authorities as contemplated by this Agreement;

 

5.2.4
exercise rights granted hereunder to the Receiving Party and perform obligations of the Receiving Party hereunder; and

 

5.2.5
otherwise comply with applicable governmental laws and regulations, court orders and legal requirements.

 

5.3
Obligations of the Receiving Party

 

In
the event that a Receiving Party is required to, or shall deem it necessary to, disclose Confidential Information of the Disclosing
Party pursuant to Section 5.2, then except as otherwise expressly set forth herein, the Receiving Party (a) shall, to the extent
practicable, give reasonable advance notice to the Disclosing Party of such disclosure, and (b) if requested by the Disclosing
Party, use reasonable efforts to cooperate with the Disclosing Party's efforts to secure confidential treatment of such information.
In any event, Licensee and Licensor shall take all reasonable precautions to avoid any unauthorized use or disclosure of Confidential
Information or materials of the other Party, and Research Information, Licensed Know-How or confidential Licensed Patent Rights.

 

5.4
Permitted Disclosure by Licensee

 

Notwithstanding
the foregoing Sections 5.2 and 5.3, Licensee may disclose the existence (if not publicly disclosed previously in accordance with
this Article 5 or Section 14.5) and/or the terms of this Agreement (a) in confidence, to its lenders, investment bankers, investors
and potential investors, attorneys, financial advisors and other financial institutions of its choice for purposes of financing
the business operations of Licensee, and (b) subject to appropriate written obligations of confidentiality and non-use, to a potential
acquirer of all or substantially all of the assets of Licensee related to the subject matter of this Agreement. Notwithstanding
the foregoing Sections 5.2 and 5.3, Licensee may disclose any and all Licensed Know-How and Licensed Patent Rights (y) to Licensee's
Affiliates; its actual and potential Sublicensees; and its actual and potential business partners (and any of the directors, officers,
employees, advisors, consultants, distributors and agents of the foregoing recipients set forth in this clause (y)); provided,
however, that Licensee shall impose upon such recipients described in clause (y) appropriate written obligations of confidentiality
and non-use; and (z) to Regulatory Authorities in the Territory. Licensee may publicize and/or disclose the execution of this
Agreement and further information and developments regarding this Agreement (including in a press release(s)), subject to Section
14.5.

5.5
Survival

 

The
foregoing restrictions and obligations imposed by this Section 5 shall survive expiration or termination of this Agreement for
whatever reason.

5.6
Publication

 

Licensor
and Licensee recognize the importance to scientists of the ability to publish and present clinical trial results, and agree that
subject to the terms of this Section 5.6, Licensee shall have the right to do so. Licensor and Licensee also recognize that patent
rights in and outside the Territory can be jeopardized by submission of a manuscript or by public disclosure (including a presentation
at a scientific conference) in or outside of the Territory prior to the filing of suitable patent applications. Therefore, Licensee
agrees that, before submission to a publisher or disclosure to any other third party (including a presentation at a scientific
conference), each proposed publication or public presentation containing any Licensed Know-How pertaining to Licensed Compounds,
Research Information and/or Licensed Products (a "Proposed Public Disclosure") shall be submitted to Licensor for review
in connection with preservation of patent rights, to ensure (a) that none of Licensor's Confidential Information or Research Information
is included in the Proposed Public Disclosure, and (b) that such Proposed Public Disclosures and submissions to publishers containing
such Licensed Know-How are consistent with Licensor's intellectual property, development and commercialization plans and objectives
in the Territory. Licensor shall have sixty (60) days from receipt of such Proposed Public Disclosure to review it, which review
period may be extended for an additional thirty (30) days in the event that Licensee provides substantial and reasonable need
for such extension. During such period, as extended, Licensor may request the removal of any of its Confidential Information or
any Research Information that is contained in the Proposed Public Disclosure and, in the event Licensor determines a need to delay
the Proposed Public Disclosure to protect or preserve patent rights, Licensor shall request such delay in writing within such
review period (as extended), and Licensee will delay such Proposed Public Disclosure for an additional period of up to one hundred
twenty (120) days to permit Licensor to file a patent application(s). If requested by Licensor, Licensee shall remove from such
Proposed Public Disclosure any of Licensor's Confidential Information and/or or Research Information (as applicable). Scientists
employed by Licensor or Licensee will be expected to treat matters of authorship in a proper, collaborative spirit, giving credit
where it is due and proceeding in a manner that complies with this Section 5.6 and fosters cooperation and communication.

6.
INTELLECTUAL PROPERTY RIGHTS; OWNERSHIP

6.1
Ownership

 

Licensor
owns all patents and other intellectual properties licensed to Licensee pursuant to this Agreement. Any extant intellectual property
rights in respect of the Licensed Compounds, Research Information, the Licensed Know-How, the Licensed Patent Rights, and any
intellectual property rights that may be discovered, identified, developed, generated, modified, obtained or derived by Licensor
or Licensee in future activities pertaining to the Licensed Compounds, Research Information, the Licensed Know-How, the Licensed
Patent Rights and Licensed Products will be solely and exclusively owned by Licensor.

6.2
Patent Prosecution

 

Licensee
shall have the full right and authority to, and shall use commercially reasonable efforts to, prepare, file, prosecute and maintain
all Licensed Patent Rights in the Field in the Territory (which Licensed Patent Rights shall, for greater certainty, be the sole
and exclusive property of Licensor), in consultation with Licensor, using counsel of its choice reasonably acceptable to Licensor.
To the extent practicable, Licensee shall provide Licensor with drafts of substantive prosecution papers to be submitted to patent
offices in the Territory (with reasonable advance notice, so that Licensor may have an opportunity to comment in a timely fashion),
and Licensee shall give suggestions from Licensor reasonable consideration (but without any obligation to incorporate or accept
such suggestions). Licensee shall provide Licensor with copies of all substantive prosecution papers submitted to or received
from patent offices in the Territory, including patent applications and amendments thereto, relating to the Licensed Patent Rights.
Licensor shall cooperate with and assist Licensee in connection with such preparation, filing, prosecution and maintenance of
Licensed Patent Rights, at no charge to Licensee for the time of Licensor's employees; provided that Licensee shall reimburse
Licensor for its reasonable out-of-pocket expenses incurred in connection therewith. Licensee shall not abandon or discontinue
prosecution of any patent application or patent within the Licensed Patent Rights without giving Licensor at least ninety (90)
days' written notice prior to any applicable deadline; provided, however, Licensee may take ministerial and non-material procedural
actions regarding the Licensed Patent Rights without providing prior written notice to Licensor. If Licensee provides such notice,
Licensor may continue prosecution and/or maintenance of such abandoned or discontinued patent application or patent within the
Licensed Patent Rights at its sole discretion and expense, and such thereafter such patent application or patent within the Licensed
Patent Rights shall no longer be included in the Licensed Patent Rights hereunder.

 

6.3
Expenses

 

6.3.1
Patent Expenses. All costs incurred by Licensee for patent and patent application preparation, filing, prosecution, issuance and
maintenance in connection with patent applications and patents within the Licensed Patent Rights in the Territory shall be borne
solely by Licensee.

 

6.3.2
Technology Transfer Expenses. To the extent that members of the Licensor's executive management team, including, without limitation,
Dr. Eric von Hofe, PhD, the President of Antigen Express, Inc., are required to travel to the Territory from time-to-time in order
to facilitate the performance of this Agreement by the Parties, the Licensee shall reimburse the Licensor for any and all customary
and reasonable travel expenses incurred in that respect.

7.
INTELLECTUAL PROPERTY PROTECTION

7.1
Notice of Suspected Infringement of Licensed Patent Rights

Each
Party shall inform the other Party of any threatened or suspected infringement of any Licensed Patent Right in the Field in the
Territory coming to its attention, or of the institution of any third-party action or proceeding that may adversely impact any
Licensed Patent Right in the Field in the Territory.

7.2
Control of Infringement Actions

 

7.2.1
Licensee shall have the first right, but not the obligation, at its sole expense, to take action in its own name, and in Licensor's
name as a nominal party if reasonably necessary, against any such alleged infringer, or in any such third-party action or proceeding.
In such event, after each Party has recovered all of its costs and expenses from such action or proceeding, Licensee shall be
entitled to all remaining recoveries in any such action or proceeding; provided that any such remaining recoveries shall be deemed
to be Net Sales, and Licensee shall pay Licensor royalties on such Net Sales at the rates provided in this Agreement. Licensor
will assist Licensee, at Licensee's expense, in such actions or proceedings, if reasonably requested by Licensee or required by
law. Licensor shall have the right to participate and to be represented in any such action or proceeding by its own counsel, at
its own expense. In the event that any Licensed Patent Rights that are the subject of such action or proceeding have been sublicensed
by Licensee hereunder, any such Sub-licensee shall also have the right to participate in such prosecution or defense. Licensee
shall not settle any such action or proceeding without Licensor's written consent, not to be unreasonably withheld or delayed,
if such settlement would, in Licensor's reasonable judgment, adversely affect the scope or validity of the Licensed Patent Rights.

7.2.2
If Licensee, its Affiliate or Sub-licensee elects not to take action within six (6) months after being informed of such alleged
infringement or such third-party action or proceeding (or, if shorter, within thirty (30) days before any applicable deadline),
Licensor may take action, at its sole expense, and shall be entitled to all damages assessed in any such action or proceeding.

7.2.3
The Party undertaking action under either Section 7.2.1 or 7.22 shall keep the other Party informed of the status of the matter
on an ongoing basis.

 

7.3
Notice of a Claim of Infringement by a Third Party

 

In
the event that a third party at any time threatens to or brings suit against Licensee, Licensor, or Licensee's Affiliate(s) or
Sub-licensee(s) alleging infringement of any third-party patent or other intellectual property right due to the research, development,
manufacture, use, sale, offer for sale or importation of any Licensed Compound or Licensed Product in the Field in the Territory
(a "Third-Party Claim"), the Party receiving notification of the Third-Party Claim shall promptly notify the other Party,
enclosing a copy of all pleadings served, if any.

 

7.4
Defense of a Third-Party Claim

 

Licensee
shall have the right, in its discretion, to control the defense of such Third-Party Claim in its own name (and in Licensor's name
as a nominal party, if reasonably necessary), provided that Licensee shall not settle such matter in any way that imposes an unreimbursed
obligation on Licensor without Licensor's consent, not to be unreasonably withheld or delayed, and such defense, including settlement
of the matter (which settlement may, in Licensee's discretion, include obtaining a license from such third party), shall be at
Licensee's own expense and under its direction and control. Licensor, at Licensee's expense, will reasonably assist Licensee in
such defense, if so requested. In addition, Licensor shall have the right to participate and be represented in any defense of
such Third-Party Claim by its own counsel, at its own expense. Any judgments, settlements or damages payable with respect to a
Third-Party Claim shall be paid by Licensee, subject to any claims against the other Party for breach of or for indemnification
under this Agreement, or any other remedies that are otherwise available at law or in equity.

8.
REPRESENTATIONS AND WARRANTIES

8.1
Representations and Warranties of Licensee

 

Licensee
hereby represents and warrants to Licensor, as of the Effective Date, that:

8.1.1
It has the right, power and authority to enter into this Agreement and to perform its obligations hereunder.

8.1.2
This Agreement has been duly executed and delivered by Licensee, and is a legal, valid and binding obligation enforceable against
Licensee in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, arrangement, moratorium and
other laws relating to or affecting creditors' rights generally and equitable principles.

8.1.3
The execution, delivery and performance of this Agreement, and the rights and licenses granted hereunder, do not conflict with,
violate or breach any agreement to which Licensee is a party, and there are no agreements, assignments or encumbrances of Licensee
that are inconsistent with the provisions of this Agreement.

8.1.4
The execution and delivery by Licensee of this Agreement and the performance by Licensee of the obligations under this Agreement
require no governmental or regulatory approvals to be obtained on the part of Licensee, or, if required, Licensee has obtained
or will have obtained such approvals.

8.2
Representations, Warranties and Covenants of Licensor

Licensor
hereby represents, warrants and covenants to Licensee, as of the Effective Date, that:

8.2.1
The Board has granted Licensor all requisite right, power and authority to enter into this Agreement and to perform Licensor's
obligations hereunder and Licensor is fully and lawfully empowered to grant the rights and licenses granted to Licensee herein.

8.2.2
This Agreement has been duly executed and delivered by Licensor, and is a legal, valid and binding obligation enforceable against
Licensor in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, arrangement, moratorium and
other laws relating to or affecting creditors' rights generally and equitable principles.

8.2.3
The execution, delivery and performance of this Agreement, and the rights and licenses granted to Licensee hereunder, do not conflict
with, violate or breach any agreement to which Licensor is a party, and there are no agreements, assignments or encumbrances in
existence to which Licensor is a party that are inconsistent with the provisions of this Agreement. Licensor has not granted,
and will not grant, any license or other right in any of the Licensed Compounds, Licensed Patent Rights, Research Inventions,
or Licensed Know-How that conflicts with any of the licenses or rights granted to Licensee under this Agreement.

8.2.4
Exhibit A sets forth a true and complete list of all patents and patent applications filed on or before the Effective Date
in the Territory that are Licensed Patent Rights, and all such patents and patent applications are owned and Controlled by Licensor.

 

8.2.5
To the best of the Licensor' s knowledge, Information, and belief, no patents within the Licensed Patent Rights are being infringed
by a third party.

 

8.2.6
The Licensor has not recei、red any written notice from any third party, including any Governmental Body, claiming any ownership
interest in the Licensed patent Rights or the Licensed Compounds (whether by inventorship, assignment or otherwise).

 

8.2.7
(a) No lawsuit has been filed against Licensor, nor has any third party threatened writing to file a lawsuit against Licensor,
with respect to the Licensed Compounds, Licensed Products or Licensed Patent Rights; and (b) no patent or patent application within
the Licensed Patent Rights is or has been involved in any reissue, reexamination, interference, opposition or equivalent or similar
proceeding to which Licensor is a party and (c) the Licensed Patent Rights are not subject to any judgments or settlements against
or owed by Licensor.

 

8.2.8
The execution and delivery by Licensor of this Agreement, and the performance by Licensor Of the obligations under this Agreement,
require no governmental or regulatory approvals to be obtained on the part Of Licensor, or, if required, Licensor has obtained
or will obtain such approvals.

 

8.2.9
Licensor has not knowingly failed to disclose to Licensee any material adverse facts regarding (a) communications to or from any
pertinent Regulatory Authority with respect to the Licensed Compounds or Licensed Products; and/or (b) any adverse events or product
recalls or withdrawals with respect to the Licensed Compounds or Licensed Products.

 

8.3
Disclaimer ofWarranties

 

Except
as otherwise expressly set forth in this Article 8, and without affecting either party's obligations under this agreement, neither
licensor nor licensee makes any representation or extends any warranty of any kind, either express or implied, to the other party
with respect to any patent rights, know-how, materials, rights, clinical data or any other subject matter of this agreement, and
each party hereby disclaims all implied warranties, including implied warranties of merchantability, fitness for a particular
purpose and non-infringement, with respect to any and all of the foregoing. Each party hereby disclaims any representation or
warranty that the development, manufacture of commercialization of any licensed product pursuant to this agreement will be successful
or that any particular sales level with respect to the licensed products will be achieved.

9.
REGULATORY MATTERS    

9.1
Export Controls

 

Licensee
and its Affiliates and Sub-licensees shall comply with all applicable laws, rules and regulations of any relevant Governmental
Body in the Territory in the exercise of their rights and discharge of their responsibilities under this Agreement, including
export laws, restrictions and regulations of any United States or foreign agency or authority in the Territory, and will not export
or re-export, or allow or authorize the export or re-export, of any Licensed Compound, Licensed Products, Technical Information,
material, technology or other information it obtains or learns pursuant to this Agreement in violation of this Agreement or of
any such laws, restrictions or regulations in the Territory.

10.
INDEMNIFICATION, INSURANCE AND LIMITATION OF LIABILITY

10.1
Indemnification by Licensee

 

Licensee
shall indemnify, defend and hold harmless Licensor and its Affiliates, and each of their respective employees, officers, directors,
and agents (each, a "Licensor Indemnitee") from and against any and all liability, loss, damage, penalty, expense (including
reasonable attorneys' fees and expenses) and cost (collectively, "Losses") resulting from, arising out of, or relating
to:

 

10.1.1
Licensee's failure to perform its obligations under this Agreement or Licensee's or its Affiliates' or Sub-licensees' negligence
or willful misconduct in the course of such performance;

10.1.2
any and all claims arising from the research, development, use, manufacture, sale, offer for sale, importation, distribution,
marketing and promotion of the Licensed Products in the Territory by Licensee or any of its Affiliates or Sub-licensees; or

10.1.3
a breach by Licensee of its representations and warranties under this Agreement;

provided
that Licensee's obligations under this Section 10.1 shall not apply to the extent such claims, actions or suits result from the
gross negligence or willful misconduct of any Licensor Indemnitee.

10.2
Indemnification by Licensor

 

Licensor
shall indemnify, defend and hold harmless Licensee and its Affiliates and Sub-licensees, and each of their respective employees,
members, officers, directors and agents (each, a "Licensee Indemnitee") from and against any and all Losses resulting
from, arising out of, or relating to:

10.2.1
claims for death of or injury to any person(s) resulting directly from Licensor's negligence or willful misconduct;

 

or

 

10.2.3
a breach by Licensor of its representations and warranties under this Agreement;

provided
that Licensor's obligations under this Section 10.2 shall not apply to the extent such claims, actions or suits result from the
gross negligence or willful misconduct of any Licensee Indemnitee.

10.3
Other Remedies

 

The
foregoing indemnification provisions shall not be exclusive, and shall be in addition to any other remedies available to the Parties
hereunder.

 

10.4
Insurance

 

On
a date that is no later than Licensee's initiation of the first human clinical study of a Licensed Product in the Field in the
Territory, Licensee shall, at its own cost, obtain and carry in full force and effect, during the remainder of the term of this
Agreement and thereafter as provided below, insurance, including comprehensive commercial general liability insurance (including
contractual liability and product liability insurance), in amounts and subject to deductibles customary in the pharmaceutical
industry and sufficient to cover its obligations under this Agreement. Upon the request of Licensor, Licensee shall provide Licensor
with Certificates of Insurance evidencing compliance with this Section 10.4.Licensee shall continue to maintain such insurance
for so long as it, or any Affiliate or Sub-licensee, continues to develop, manufacture or sell Licensed Products in the Field
in the Territory, and thereafter as may be required to cover manufacture or sales of distributed Licensed Products in the Field
in the Territory.

 

10.5
Limitation of Liability

 

In
no event will Licensor or any Licensor Indemintees be liable to any Licensee Indemnitees for any indirect, incidental, special,
exemplary of consequential damages, including lost profits or revenues, arising out of or in connection with this agreement or
any breach thereof whether based in contract, tort (including negligence and strict liability) or otherwise, to the maximum extent
allowed by law.

11.
TERM AND TERMINATION

11.1
Term

 

Unless
sooner terminated in accordance with this Agreement, the term of this Agreement shall commence on the Effective Date and shall
continue, in the territory, until the later of: (a) expiration of the last-to-expire patent within the Licensed Patent Rights
in such country, or (b) the fifteenth (15th) anniversary of the first Approved Sale of a Licensed Product in such country. Following
such expiration, Licensee shall have a fully paid-up license that corresponds to the license granted to Licensee in Section 3.1.

11.2
Termination

 

11.2.1
In the event that Licensee or Licensor breaches a material undertaking or obligation hereunder, the other Party shall have the
right, without limitation of any other right it has under this Agreement on account of such breach, to terminate this Agreement
on ninety (90) days (or, in the case of breach of an obligation to pay money, thirty (30) days) prior written notice specifying
such breach and demanding its cure; provided, however, that if the alleged breaching Party shall cure such breach during such
ninety (90)-day (or thirty (30)-day, if applicable) period, then such notice of termination shall be null and void; otherwise,
this Agreement shall be terminated on and after the expiration of said ninety (90)-day (or thirty (30)-day, if applicable) period.

11.2.2
This Agreement may be terminated at any time by a Party upon the filing or institution of bankruptcy, reorganization, liquidation
or receivership proceedings by or against the other Party, or upon an assignment of a substantial portion of its assets for the
benefit of creditors by such other Party; provided, however, that in the event of any involuntary bankruptcy or receivership proceeding,
such right to terminate shall only become effective if the proceeding is not dismissed within sixty (60) days after the filing
thereof.

11.2.3
At any time after eighteen (18) months following the Effective Date, this Agreement may be terminated in Licensee's sole discretion
on sixty (60) days prior written notice to Licensor.

 

11.3
Effect of Termination or Expiration

 

11.3.1
Termination of this Agreement under any provision herein shall not affect the obligation of Licensee to pay Licensor any royalty
or other payments which have accrued and are unpaid as of the date of termination, nor shall the same prejudice any other accrued
right of Licensor or Licensee under this Agreement. For the sake of clarity, if a payment obligation has not accrued as of the
effective date of termination of this Agreement, then, except as expressly set forth herein, any subsequent event or achievement
that would have resulted in accrual of such payment obligation — if the Agreement had not been terminated — shall
have no effect on any payment(s) hereunder. Within ninety (90) days after termination, Licensee shall render to Licensor a written
statement of the kind required by Section 4.2.6 hereof with respect to any due and unpaid royalties, and shall accompany such
a statement with payment to cover same.

11.3.2
In the event of termination of this Agreement, other than a termination of this Agreement by Licensee pursuant to Section 11.2.3
or a termination of this Agreement by Licensor pursuant to Section 11.2.1 or Section 11.2.2, Licensee, its Affiliates and Sublicensees
shall be entitled, for a period of twelve (12) months thereafter, to sell Licensed Products existing or being manufactured on
the date of termination; provided that Net Sales from sales of such Licensed Products shall be subject to royalty payments under
Section

4.2.

11.3.3
If either party has a right to terminate this Agreement pursuant to Section I I .2.1 or 11.2.2, then such party may elect (in
its sole discretion) to do one of the following: (a) terminate this Agreement and retain its right to pursue any and all remedies
permitted at law or in equity (including contract damage remedies), or (b) continue the Agreement while simultaneously pursuing
any and all remedies permitted at law or in equity (including contract damage remedies). Maybe we could suspend payments until
adjudication.

 

11.4
Survival

 

Expiration
or termination of this Agreement, whether in whole or in part, shall not relieve the Parties of any obligation accruing prior
to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights and
the legal and equitable remedies of the Parties accrued or accruing under this Agreement prior to expiration or termination, subject
to the terms and conditions of this Agreement (including, for the avoidance of doubt, the right to enforce the terms and conditions
set forth herein without terminating this Agreement, and further including any obligations of a Party that are expressly identified
in this Agreement as surviving, or that by their nature or context logically survive, termination, relinquishment or expiration
of this Agreement). Without limiting the foregoing sentence, the provisions of Article 1 (to the extent definitions are embodied
in the following listed Articles and Sections of this Agreement) and Articles 5, 10 and 13, and Sections 6.1, 11.3, 14.5, 14.6,
14.9, 14.10 shall survive any expiration or termination of this Agreement. Except as set forth in this Article I l, upon termination
or expiration of this Agreement all other rights, licenses and obligations of the Parties shall cease.

12.
ASSIGNMENT

Neither
Party shall have any right or ability to assign or transfer this Agreement or any obligations or benefit under this Agreement
(whether by operation of law or otherwise) without the written consent of the other Party (and any unauthorized purported assignment
will be void). Any Change of Control of Licensee shall be deemed an assignment of this Agreement for purposes of this Section.
Notwithstanding the foregoing Licensee may assign this Agreement, without the consent of Licensor, to an Non-Afflliate Acquirer
in connection with the transfer or sale of all or substantially all of its assets or business to which this Agreement relates
to such Non-Affiliate Acquirer, or in the event of its merger or consolidation with, acquisition by, or sale to such a Non-Affiliate
Acquirer; provided that such Non-Affiliate Acquirer (a) agrees in writing to be bound by the terms and conditions of this Agreement;
and (b) has the financial and other resources to perform its obligations under this Agreement. Subject to the foregoing, this
Agreement will be binding upon and inure to the benefit of the Parties and the successors and permitted assigns of Licensee and/or
Licensor.

13.
NOTICES AND ADDRESSES

13.1
Delivery of Notices

 

Any
written communication, notice, report or payment shall be deemed to be sufficiently given when delivered in person, or sent by
confirmed facsimile, or two (2) days after being sent by internationally recognized overnight courier (e.g., FedEx, DHL, etc.),
if addressed and sent to a Party at its address set forth below.

 

	 	If
    to Licensor:	 
	 	Generex
    Biotechnology Corporation	 
	 	4145
    North Service Road	 
	 	Suite
    200	 
	 	Burlington,
    Ontario, Canada L7L 6A3	 
	 	Attentions	Mark
    A. Fletcher	 
	 	 	Executive
    Vice-President & General Counsel	 
	 	 	mfletcher@generex.com	 
	 	 

                    
	 
	 	If
    to Licensee:	 
	 	Shenzhen
    BioScien Pharmaceuticals CO. LTD.	 
	 	 	 
	 	NAME
    ADDRESS: Room 311, First Building, Shenzhen Overseas Venture Park (Longgang), Shenzhen 518116, China
	 	Email:	2575962704@qq.com

 

13.2
Change of Address

 

Either
Party may change its mailing address for the purpose of this Agreement by giving the other Party notice of such change in accordance
with Section 13.1 at least fifteen (15) days prior to the date upon which the change is to become effective.

 

14.
MISCELLANEOUS

Agreement
 

 

14.1
Entire Agreement

 

This
Agreement constitutes the entire understanding between the Parties with respect to the subject matter hereof, and except for the
CDA, which shall continue in full force and effect with respect to any disclosures by a Party made prior to the Effective Date,
the Option Agreement, and the Purchase Agreement, this Agreement shall supersede and replace all prior agreements, understandings,
writings and discussions between the Parties relating to said subject matter.

 

14.2
Amendment; Waiver

 

This
Agreement may be amended, and any of its terms or conditions may be waived, only by a written instrument executed by Licensor
and Licensee or, in the case of a waiver, by the Party waiving compliance. The failure of either Licensor or Licensee at any time
or times to require performance of any provision hereof shall in no manner affect its rights to enforce the same at a later time.
No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing
waiver of such condition or term or any other condition or term.

14.3
Titles; Captions

 

All
titles and captions in this Agreement are for convenience only, and shall not be interpreted as having any substantive meaning.

 

14.4
Independent Contractors

 

Except
as set forth in Article 8, nothing in this Agreement authorizes Licensee or Licensor to act as agent for the other Party as to
any matter. Licensee and Licensor are not Affiliates of one another; and their relationship is that of independent contractors.
Nothing in this Agreement will be deemed to create an agency, joint venture, amalgamation, partnership, employment, franchise,
fiduciary of similar relationship between them.

14.5
Publicity and Disclosure

 

Except
as set forth in Article 5, neither Licensor nor any of its Affiliates shall use the name of Licensee or any Affiliate or Sub-licensee
of Licensee, or any director, employee, officer, or representative of Licensee, in any advertising, press release, promotion or
sales literature without the prior written approval of Licensee, which shall not be unreasonably withheld or delayed. Except as
set forth in Article 5, neither Licensee nor any of its Affiliates or Sub-licensees shall use the name of Licensor or any Affiliate
of Licensor, or any director, employee, officer, or representative of Licensor, in any advertising, press release, promotion or
sales literature without the prior written approval of Licensor, which shall not be unreasonably withheld or delayed.

14.6
Use of Trademarks

 

Licensee
and its Affiliates and Sub-licensees may use any trademark(s) owned or Controlled by Licensee or any of its Affiliates or Sub-licensees
in connection with the Licensed Products to be made, used, sold, offered for sale, imported or distributed in the Territory. Licensor
shall have no ownership or other right in or to such trademark(s) of Licensee, its Affiliates or its Sub-licensees.

14.7
Marking

 

All
Licensed Products shall be marked with the patent numbers of issued patents within the Licensed Patent Rights that cover such
Licensed Products, to the extent practicable and permitted by law in countries in which such markings have notice value against
infringers of patents.

 

14.8
Severability

 

If
any provision of this Agreement is or becomes invalid, is ruled illegal by any court of competent jurisdiction or is deemed unenforceable
under the current applicable law from time to time in effect during the term hereof, it is the intention of the Parties that the
remainder of this Agreement shall not be affected thereby. It is further the intention of the Parties that, in lieu of each such
provision, there shall be substituted or added as part of this Agreement a provision which shall be as similar as possible in
economic business objectives, as intended by the Parties, to such invalid, illegal or unenforceable provision, but which shall
be valid, legal and enforceable.

14.9
Governing Law & Language

 

The
construction and performance of this Agreement shall be governed by the laws of the State of New York, USA without regard to conflicts
of laws principles that would require the application of any other law. In the event of any discrepancies between the English
language version of this Agreement and any other version, the English language version shall be the original and shall control
in the event of any question concerning the meaning or import of its terms. The English language shall be the official language
of all correspondence, meetings and arbitration between the Parties.

 

14.10
Dispute Resolution

14.10.1
Disputes. The Parties recognize that disputes as to certain matters may arise from time-to-time during the term of the Agreement.
It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement
in an expedient manner and without resort to litigation. The Parties shall attempt to settle any such dispute through good faith
negotiations in the spirit of mutual cooperation between business executives with authority to resolve the dispute. To accomplish
this objective, and with respect to all disputes hereunder, the Parties agree to follow the procedures set forth in this Section
14.10 if and when a dispute between the Parties arises under this Agreement.

14.10.2
Escalation. Prior to taking action as provided in Section 14.10.3 of this Agreement, the Parties shall first submit such dispute
to Licensee's Chief Executive Officer and to the President & Chief Executive Officer of Licensor (the Heads" ) for resolution.
The Heads to whom any dispute is submitted shall attempt to resolve the dispute through good faith negotiations over a reasonable
period, not to exceed forty-five (45) calendar days following one Party's receipt of a notice of dispute from the other Party,
unless the Heads mutually agree in writing to extend such period of negotiation. Such 45-day period shall be deemed to commence
on the date the dispute was submitted to the Heads. All negotiations pursuant to this Section 14.10.2 shall be confidential, "without
prejudice", and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.

14.10.3
Arbitration. Any dispute that is not resolved by negotiation and/or escalation pursuant to Sections 14.10.1 and/or 14.10.2 shall,
upon the submission of a written request of either Party to the other Party, be submitted to China International Economic and
Trade Arbitration Commission (CIETAC) for arbitration in Beijing, China, which shall be conducted in accordance with CIETAC's
arbitration rules in effect at the time of applying for arbitration. The presiding arbitrator shall not be a Chinese national
or a citizen of the United States. The arbitral award is final and binding upon both Parties, shall be the sole and exclusive
remedy of the Parties, and shall be enforceable in any court of competent jurisdiction. The English language shall be used throughout
the arbitral proceedings. Relevant documents in other languages shall be translated into English if the arbitrators so direct.
The Parties agree that they shall share equally the cost of the arbitration filing and hearing fees. Each Party shall bear its
own attorneys' and expert fees and all associated costs and expenses.

 

14.11
Counterparts

 

This
Agreement may be executed by original or facsimile signature in several counterparts, all of which shall be deemed to be originals,
and all of which shall constitute one and the same Agreement. Notwithstanding the foregoing, the parties shall deliver original
execution copies of this Agreement to one another as soon as practicable following execution thereof.

[The
remainder of this page intentionally left blank.]

 

 

 

    	 	5	 

     

    

 

 

 

    	 	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]